Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 9:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1441–1464 of 5,233 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Germ Cell Tumor Clear all
Recruiting Phase 1Phase 2 Interventional

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

NCT05417594
View directory record Official record
Conditions
Advanced Solid Malignancies
Interventions
AZD9574, Temozolomide (TMZ), [11C]AZ1419 3391, Trastuzumab Deruxtecan (T-DXd), Datopotamab Deruxtecan (Dato-DXd)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
695 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
11
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 31, 2026, 9:51 AM EDT
Completed Phase 2 Interventional

Efficacy of Distant Healing in Glioblastoma Treatment

NCT00029783
View directory record Official record
Conditions
Glioblastoma
Interventions
Distant Healing
Procedure
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2006 · Synced Oct 31, 2026, 9:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pediatric Phase I Trial of RMP-7 and Carboplatin in Brain Tumors

NCT00001502
View directory record Official record
Conditions
Brain Neoplasms, Glioma, Medulloblastoma
Interventions
RMP-7 and carboplatin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1996 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 31, 2026, 9:51 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma

NCT03690869
View directory record Official record
Conditions
Relapsed Solid Tumor, Refractory Solid Tumor, Relapsed Central Nervous System Tumor, Refractory Central Nervous System Tumor, Diffuse Intrinsic Pontine Glioma, High Grade Glioma
Interventions
cemiplimab (monotherapy), cemiplimab (maintenance), Conventional or hypofractionated, Re-irradiation
Drug · Radiation
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
Up to 25 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
20
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Oct 31, 2026, 9:51 AM EDT
Not listed Phase 2 Interventional

Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III Melanoma

NCT00492505
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
cisplatin, sorafenib tosylate, tamoxifen citrate, adjuvant therapy
Drug · Procedure
Lead sponsor
San Diego Pacific Oncology & Hematology Associates
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Encinitas, California
Source: ClinicalTrials.gov public record
Updated Jan 10, 2014 · Synced Oct 31, 2026, 9:51 AM EDT
Terminated Early Phase 1 Interventional

Radiosurgery Plus Bevacizumab in Glioblastoma

NCT01086345
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma, Brain Tumor
Interventions
radiosurgery, bevacizumab, irinotecan hydrochloride
Radiation · Biological · Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 3, 2018 · Synced Oct 31, 2026, 9:51 AM EDT
Completed Phase 3 Interventional Results available

Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma

NCT02678572
View directory record Official record
Conditions
Ocular Melanoma, Uveal Melanoma
Interventions
Melphalan/HDS
Combination Product
Lead sponsor
Delcath Systems Inc.
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
9
States / cities
Tucson, Arizona • Palo Alto, California • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 31, 2026, 9:51 AM EDT
Completed Not applicable Interventional

Study of 1cm Versus 2cm Margins for the Surgical Treatment of cT2N0M0 Melanoma

NCT03034395
View directory record Official record
Conditions
Malignant Melanoma
Interventions
Wide Local Excision
Procedure
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Oct 31, 2026, 9:51 AM EDT
Completed Not applicable Interventional

Safety and Efficacy of Silicone Oil Tamponade for Surgical Attenuation of Radiation Damage in Choroidal Melanoma

NCT01460810
View directory record Official record
Conditions
Choroidal Melanoma
Interventions
1000CsK Silicon Oil Tamponade
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 7, 2022 · Synced Oct 31, 2026, 9:51 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)

NCT02771626
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma (ccRCC), Melanoma, Non-small Cell Lung Cancer (NSCLC)
Interventions
CB-839, Nivolumab
Drug
Lead sponsor
Calithera Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
17
States / cities
Scottsdale, Arizona • Palo Alto, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2023 · Synced Oct 31, 2026, 9:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Strategies to Promote Skin Health

NCT03237013
View directory record Official record
Conditions
Skin Cancer, Skin Cancer Melanoma, Squamous Cell Carcinoma, Basal Cell Carcinoma
Interventions
Facial Morphing Intervention, Mindfulness Intervention
Behavioral
Lead sponsor
San Diego State University
Other
Eligibility
18 Years and older
Enrollment
219 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 5, 2019 · Synced Oct 31, 2026, 9:51 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors

NCT01628913
View directory record Official record
Conditions
Pancreatic Neuroendocrine Tumors (pNET)
Interventions
BEZ235, Everolimus
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
4
States / cities
Los Angeles, California • Aurora, Colorado • Lexington, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2016 · Synced Oct 31, 2026, 9:51 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

NCT02460224
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
LAG525, PDR001
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
490 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
6
States / cities
New York, New York • Durham, North Carolina • Houston, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2022 · Synced Oct 31, 2026, 9:51 AM EDT
Completed Phase 1 Interventional

Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers

NCT02639026
View directory record Official record
Conditions
Metastatic, Melanoma, Non Small Cell Lung Cancer (NSCLC), Breast Cancer, Pancreatic Cancer
Interventions
Radiotherapy, MEDI4736, Tremelimumab
Radiation · Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Oct 31, 2026, 9:51 AM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Young Patients Who Are Undergoing Surgery for Malignant Glioma

NCT00107185
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
therapeutic autologous dendritic cells
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
1 Year to 18 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Oct 31, 2026, 9:51 AM EDT
Recruiting Phase 1Phase 2 Interventional

Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors

NCT06625190
View directory record Official record
Conditions
Neuroblastoma, Rhabdomyosarcoma, Synovial Sarcoma, Peripheral Nerve Sheath Tumors, Clear Cell Sarcoma, Alveolar Soft Part Sarcoma, Desmoplastic Small Round Cell Tumor, Chordoma, Rhabdoid Tumor, Epithelioid Sarcoma, Myoepithelial Tumor, Osteosarcoma, Ewing Sarcoma, Wilms Tumor
Interventions
Miltenyi CliniMACS Prodigy ® system, Zoledronic acid
Device · Drug
Lead sponsor
University of Florida
Other
Eligibility
6 Months to 25 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 31, 2026, 9:51 AM EDT
Completed Phase 2 Interventional Results available

Fluorescence Detection of Adult Primary Central Nervous System Tumors With Tozuleristide and the Canvas System

NCT04743310
View directory record Official record
Conditions
Central Nervous System Tumor
Interventions
tozuleristide, Canvas imaging system, Surgical resection of tumor
Drug · Device · Procedure
Lead sponsor
John Yu
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 31, 2026, 9:51 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma

NCT01236560
View directory record Official record
Conditions
Brain Stem Glioma, Cerebral Astrocytoma, Childhood Cerebellar Anaplastic Astrocytoma, Childhood Cerebral Anaplastic Astrocytoma, Childhood Spinal Cord Neoplasm
Interventions
Bevacizumab, Temozolomide, Vorinostat
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
3 Years to 21 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
124
States / cities
Birmingham, Alabama • Downey, California • Loma Linda, California + 98 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 31, 2026, 9:51 AM EDT
Completed Phase 1 Interventional

Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma

NCT01808820
View directory record Official record
Conditions
Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma, High Grade Glioma
Interventions
Dendritic Cell Vaccine, Tumor Lysate, Imiquimod, Leukapheresis
Biological · Drug · Procedure
Lead sponsor
Macarena De La Fuente, MD
Other
Eligibility
13 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Oct 31, 2026, 9:51 AM EDT
Recruiting Phase 1 Interventional

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

NCT04119024
View directory record Official record
Conditions
Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Recurrent Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Uveal Melanoma, Acral Melanoma, Neuroendocrine Tumors, Paraganglioma, Pheochromocytoma, Adrenocortical Carcinoma, Pancreatic Neuroendocrine Tumor, Thyroid Cancer, Breast Cancer, Lung Adenocarcinoma, Head and Neck Squamous Cell Carcinoma
Interventions
Biopsy, Biospecimen Collection, Computed Tomography, Cyclophosphamide, Fludarabine Phosphate, Fludeoxyglucose F-18, IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells, Magnetic Resonance Imaging, Positron Emission Tomography
Procedure · Drug · Other + 1 more
Lead sponsor
Anusha Kalbasi
Other
Eligibility
18 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Duarte, California • Los Angeles, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 31, 2026, 9:51 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies

NCT04772989
View directory record Official record
Conditions
Advanced Solid Tumor, Non Small Cell Lung Cancer (NSCLC), Melanoma, Cervical Cancer, Multiple Myeloma, Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma (DLBCL), Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer
Interventions
AB308, Zimberelimab
Drug
Lead sponsor
Arcus Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
15
States / cities
Los Angeles, California • Jacksonville, Florida • Goshen, Indiana + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Oct 31, 2026, 9:51 AM EDT
Terminated Phase 3 Interventional Results available

PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma

NCT02288897
View directory record Official record
Conditions
Cutaneous Melanoma
Interventions
PV-10 (10% rose bengal disodium), Dacarbazine, temozolomide or talimogene laherparepvec
Drug
Lead sponsor
Provectus Biopharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
12
States / cities
San Diego, California • Miami Beach, Florida • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2022 · Synced Oct 31, 2026, 9:51 AM EDT
Completed Phase 1 Interventional Results available

Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer

NCT02475213
View directory record Official record
Conditions
Melanoma, Head and Neck Cancer, Non Small Cell Lung Cancer, Urothelial Carcinoma
Interventions
Enoblituzumab Schedule 1, Pembrolizumab, Enoblituzumab Schedule 2, retifanlimab
Biological
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
20
States / cities
Scottsdale, Arizona • Newark, Delaware • Jacksonville, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Oct 31, 2026, 9:51 AM EDT
Completed Phase 2 Interventional Results available

Temozolomide and Radiation Therapy in Treating Patients With Gliomas

NCT00114140
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
Temozolomide, Radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2022
U.S. locations
45
States / cities
Phoenix, Arizona • Los Angeles, California • Newark, Delaware + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2024 · Synced Oct 31, 2026, 9:51 AM EDT